The results of this study indicate that in CRC with p53 mutations, WEE1 inhibitors induce cell cycle changes, apoptosis, and suppressed cell proliferation in vitro and in vivo; these effects were followed by activation of tumor immunity and suppression of the stromal reaction, cell cycle progression and prolongation of the M phase, DDR, response to hypoxia, and inhibition of angiogenesis. Here, WEE1 is linked to neoplasm.